Cannabis
AMP German Cannabis Group enters into long term supply agreement with Danish medical cannabis producer Schroll Medical
AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T) (ISIN: CA00176G1028), providing German patients with a wide range of pharmaceutical grade medical cannabis products and Schroll Medical ApS (“Schroll”), a Danish cultivator of medical cannabis, announce that they have entered into a non-exclusive, three-year supply agreement for bulk and packaged EU-GMP cannabis flower which shall be branded under the AMP medical cannabis brand when offered in the German market.
Schroll is a partnership between Schroll Flowers, one of Europe’s largest producers of hydrangeas and Aphria Inc., (TSX:APHA) a leading Canadian cannabis producer, to pursue the cultivation and worldwide distribution of EU-GMP certified medical cannabis. Schroll was one of the first medical cannabis cultivators to receive a licence for cultivation and processing from the Danish government in 2018. Schroll’s large-scale greenhouse cultivation facility located in Årslev, Denmark, was EU-GMP certified by the Danish Medicines Agency in November 2019 and began production this year. The facility employs over 35 people and can produce 6,000 kilograms of dried medical cannabis flowers annually. AMP completed the on-site audit of Schroll’s production plant last week.
AMP will register products purchased from Schroll with The Federal Institute for Drugs and Medical Devices (BfArM) and has applied for an irradiation license (“AMRadV License”) for Schroll products, which AMP plans to sell in the German market.
Dr. Stefan Feuerstein, Director and President of AMP, commented, “This is our first large scale European supply agreement that will ensure we have a steady supply of high quality medical cannabis for the German market. AMP will initially import one high THC medical cannabis flower strain from Denmark which will be branded under the AMP Classic brand beginning in January 2021“.
Mr. Carsten Schroll, CEO of Schroll, commented, “Success in Germany, the largest medical cannabis market in Europe and the world, is the pathway to success in Europe as we expand our production to supply European markets. AMP’s strong distribution network and medical cannabis sales team will ensure we will be a significant supplier to Germany.”
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis3 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE3 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Humboldt2 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace